CD73 (ecto-5'-nucleotidase) is a novel immunoinhibitory protein that plays a key role for tumor growth and metastasis. Its main function is to convert extracellular ATP to immunosuppressive adenosine in concert with CD39 in normal tissues to limit excessive immune response. However, tumors take advantage of the CD73-mediated adenosinergic mechanism to protect them from immune attack. In particular, inducible expression of CD73 along with other adenosinergic molecules on both cancer cells and host cells sustains immunosuppressive tumor microenvironment by affecting multiple aspects of the immune response. Owing to its multifaceted capacity to tumor promotion as an emerging immune checkpoint, CD73 is an ideal therapeutic target for cancer treatment especially in combination with conventional therapy and/or other immune checkpoint inhibitors. In this review, we will discuss the roles of CD73 on tumor and immune cells and will highlight the therapeutic value of CD73 for combination therapy.

中文翻译：

---

靶向 CD73 以增强癌症免疫治疗。

CD73 (ecto-5'-nucleotidase) 是一种新型免疫抑制蛋白，在肿瘤生长和转移中起关键作用。其主要功能是将细胞外 ATP 与正常组织中的 CD39 一起转化为免疫抑制腺苷，以限制过度的免疫反应。然而，肿瘤利用 CD73 介导的腺苷能机制来保护它们免受免疫攻击。特别是，CD73 和其他腺苷能分子在癌细胞和宿主细胞上的可诱导表达通过影响免疫反应的多个方面来维持免疫抑制性肿瘤微环境。由于其作为新兴免疫检查点促进肿瘤的多方面能力，CD73 是癌症治疗的理想治疗靶点，特别是与常规疗法和/或其他免疫检查点抑制剂结合使用。